Avillion

Avillion is a specialized clinical development partner founded in 2013, focusing on accelerating and derisking late-stage clinical trials for biotech and pharma companies. Its core value proposition is a 'risk-sharing' partnership model where it provides funding and full operational execution in exchange for success-based milestones, backed by a claimed 100% success rate in achieving regulatory approvals. With a seasoned leadership team and experience in over 30 countries, Avillion positions itself as a capital-efficient solution for sponsors aiming to navigate complex global trials and regulatory pathways without bearing the full upfront cost and operational burden.

Integrated clinical development service model featuring global trial management, regulatory strategy, quality assurance, regionalized hands-on team structure, investigator liaison managers, and adaptive operational strategies.

Avillion competes with large, full-service Contract Research Organizations (CROs) like IQVIA, Parexel, and PPD, which offer fee-for-service models, and with other strategic development partners and venture-funding entities that also offer risk-sharing structures. Its differentiation lies in its focused late-stage expertise, claimed 100% success rate, and deeply experienced, hands-on leadership team.